Introduction
Although there is increasing evidence that the immune system plays a pivotal role in eliminating malignant cells, the concept of immunosurveillance remains a controversial issue in immunological research. 1 In murine model systems, interferon-g (IFN-g) protects against spontaneous, induced and transplanted tumors. [2] [3] [4] [5] Whether IFN-g has similar protective effects on tumorigenesis in humans remains unknown. Recently, an intronic CA-repeat polymorphism -correlated with protein expression levels -has been described in the IFN-g gene. 6 A homozygous 2/2 genotype is associated with high IFN-g production, whereas a heterozygous (2/x) and homozygous non-2 (x/x) genotype is associated with intermediate and low expression of IFN-g, respectively. 6 Further studies revealed an absolute correlation of the presence of allele 2 with the presence of an adjacent single-nucleotide polymorphism ( þ 874A-T), affecting the binding properties of NFkB to its cognate binding site. 7 þ 874T enhances binding of NFkB, thus proposing mechanistic evidence for increased levels of IFN-g expression.
In various immune-mediated diseases, such as autoimmune diseases, [8] [9] [10] [11] [12] graft-versus-host-disease 13, 14 and fibrosis in lungtransplant recipients, 15 the onset and severity of the clinical phenotype have been associated with the presence of the 12 CA-repeat polymorphism. Furthermore, the IFN-g polymorphism contributes substantially to the development of tuberculosis 16 and leprosy, 17 providing clues for the role of IFN-g in immunopathophysiological mechanisms.
We hypothesized that polymorphic IFN-g alleles may be associated with incidence, clinical manifestation and early treatment response as a surrogate marker for outcome in pediatric patients with ALL.
Patients, materials and methods

Patients
In total, 393 out of 497 patients enrolled in the ongoing ALL-BFM2000 study between July 1999 and February 2001 were selected as the study group. This cohort defines a subgroup of patients (79.1%) for which clinical data and biological material was available. The patients did not differ from the entire study population of 497 patients with respect to sex, age, immunophenotypes and leukocyte counts. An assignment to standard-, intermediate-or high-risk arm was based on cytogenetic parameters, prednisone response, induction remission status and minimal residual disease (MRD). As controls, we used samples from 207 sex-matched, registered blood donors from the Department of Transfusion Medicine.
IRB-approved informed consent or assent in the case of minors was obtained from all study subjects or their legal guardians, respectively.
Genotyping
Genotyping of the CA-repeat polymorphism in intron 1 of the IFN-g gene was performed using previously established PCR protocols 6 followed by direct blotting and chemiluminiscence detection. 18 Two homozygous control samples were established by subcloning the PCR fragments followed by direct sequencing.
Statistical analysis
The allele frequencies and genotype groups (2/2, 2/x, x/x non-2) of patients with ALL and controls were compared by w 2 -test. The frequencies of the genotype groups were compared to clinical or biological variables within the subset of patients with B-lineage and T-lineage ALL. For continuous variables, Mann-Whitney Uor Kruskall-Wallis test was applied; for categorial variables, we used w 2 -or Fisher's exact test. We only merged genotype groups or variables for direct comparisons when a preceding global test was significant (Po0.05). For all statistical calculations, SPSS for windows 11.0 software was used.
Results and discussion
Incidence
We compared the IFN-g allele frequencies of 393 patients enrolled in the ALL-BFM 2000 study (Table 1 ) with a cohort of 207 healthy blood donors. The allele frequencies of controls were comparable to previously published frequencies 6, 19 and shown to be in Hardy-Weinberg equilibrium. Comparable allele frequencies were found for affected patients and controls (P ¼ 0.696, Table 2a ). In addition, the analysis according to genotype groups and immunological phenotypes did not reveal any discernible differences (Table 2b ). These results suggest that distinct IFN-g alleles and the expression level of IFN-g are not associated with the risk to develop ALL.
Since B-lineage and T-lineage ALL represent distinct immunological and molecular disease entities, we analyzed associations of the IFN-g polymorphisms separately for the B-lineage and T-lineage patient groups, respectively.
Clinical manifestation
When we analyzed the age at the time of clinical manifestation, we found that in patients with IFN-g high-expressor alleles, the age of clinical presentation was significantly higher in patients with B-lineage ALL (median age 6 years (2/2) vs 4.3 (2/x) and 4.7 (x/x) years, P ¼ 0.021, Figure 1) . A similar but statistically not significant tendency was found in patients with T-lineage ALL (median 9.6 years (2/2) vs 8.4 (2/x) and 8.5 (x/x) years, P ¼ 0.747, Figure 1 ). Other clinical parameters, such as initial white blood cell or blast counts, were not associated with the IFN-g alleles (Table 3 ). In view of the recent data, which suggest that the first leukemia-specific cytogenetic aberrations already emerge in prenatal life, 20 our findings can be interpreted in accordance with the hypothesis that immunological host factors such as IFN-g may play a crucial role in suppressing the outgrowth of (pre)-malignant clones.
Alternatively, IFN-g polymorphisms may be associated with preferential development of certain ALL subtypes. However, our data do not support this hypothesis. First, we were not able to document a difference in the distribution of the IFN-g alleles within distinct immunologically defined subgroups (pre-pre-B, pre-B and common ALL, Table 2b ). Second, we did not find any difference of these B-lineage ALL subgroups with respect to age at presentation (data not shown).
Clinical risk parameters
We also attempted to correlate the polymorphic alleles with clinical risk parameters. The ALL-BFM 2000 study stratifies according to three early clinical response characteristics: prednisone response -defined by blast reduction in peripheral blood on day 8 of prednisone monotherapy-, cytological remission in the BM on day 33 and dynamics of MRD assessed by clone-specific PCR-analysis. As shown in Figure 2 , high-risk patients with B-lineage ALL, but not patients with T-lineage ALL, were more likely to show IFN-g low-expressor alleles (high-risk n ¼ 32, medium-plus standard-risk patients n ¼ 266, P ¼ 0.025, Fisher's exact test). In a detailed analysis of individual stratification criteria, we found that this result was mainly due to differences in prednisone response. Patients with B-lineage ALL who failed to respond to prednisone therapy at day 8 were more likely to show alleles with low IFN-g expression (poor responder n ¼ 17, good responder n ¼ 266, P ¼ 0.008, Fisher's exact test, Figure 2 ). Whether these findings are due to interferences of IFN-g and corticosteroid-receptor-dependent signalling pathways 21 remains to be shown. Although not statistically significant, B-lineage patients revealing a positive result for MRD (Figure 2 ) or failing remission on day 33 (n ¼ 5, data not shown) more frequently revealed a genotype associated with low IFN-g expression. Interestingly, in contrast to patients with B-lineage ALL, patients with T-lineage ALL did not show any discernible tendency for over-representation of any specific allele combination. This observation is in line with lineagespecific alterations in the dendritic cell compartment of patients with ALL. We have observed a specific decrease of peripheral blood dendritic cells in patients with B-lineage ALL but not in patients with T-lineage ALL (unpublished observations). Taken together, these findings suggest that distinct immunological antitumor effects may be operative in B-lineage and T-lineage Interferon-c polymorphism in childhood ALL T Cloppenborg et al Table 2 Comparison of IFN-g alleles in patients and controls Comparison of genotype groups and clinical parameters 'initial white blood cell count' (WBC), 'initial blast count' and 'gender' for patients with B-lineage and T-lineage ALL.
Interferon-c polymorphism in childhood ALL T Cloppenborg et al ALL, respectively. We cannot rule out that the nonsignificant results for the T-cell group might be due to the smaller sample size (n ¼ 69), reflecting decreased statistical power of the analysis. With respect to the age at clinical manifestation, the parallel tendency of the results between patients with B-lineage and T-lineage ALL might support this alternative hypothesis. However, with respect to the other clinical parameters, the results in the two subgroups differ strikingly, suggesting that the lack of significance cannot readily be explained by lack of statistical power. We are aware of the statistical constraints operative in testing multiple parameters (here n ¼ 9). However, strict adoptions of Bonferroni corrections would imply only a loss of statistical significance. Overall, we think that the published biological and clinical [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] relevance of the investigated polymorphism, the mechanistic model for different expression levels of IFN-g, 7 and the well-established concept of an IFN-g-dependent immunosurveillance in mice [1] [2] [3] [4] [5] support that the observed relationship between the investigated polymorphism and the associated variables in our study is real.
Several other immunologically relevant genetic polymorphisms have been assessed with respect to ALL. A polymorphism in the mannose-binding-ligand sheds some light on the influence of early infections on the risk to develop ALL. 22 Lauten et al 23 tested the association of IL10-and TNFa polymorphisms with initial response to prednisone. Unlike our study, however, these findings cannot yet readily be integrated into a mechanistic model of antitumor immunity. Recently, Dabora et al 24 confirmed a positive association between the high-expressing IFN-g allele and a lower frequency of kidney angiomyolipomas in patients with tuberous sclerosis, suggesting a tumor-suppressive effect of IFN-g. Our comprehensive analysis in a large, welldefined cohort of pediatric cancer patients now documents a potential role of IFN-g in ALL.
Owing to intrinsic methodological limitations, our correlation-study-based data cannot provide definitive proof for a causal role of IFN-g in immunosurveillance in ALL. Nevertheless, we provide, for the first time, statistical evidence for an association of IFN-g polymorphisms with relevant clinical parameters in ALL. Confirmatory studies correlating IFN-g alleles with disease markers in other tumor entities would support the concept of IFN-g-mediated immunosurveillance in humans.
Definitive proof will require more experimental data elucidating the immunological mechanisms controlling IFN-g-mediated antitumor immunity, thus providing a scientific basis for the development of novel treatment strategies.
In summary, we provide evidence that IFN-g polymorphisms are associated with age at presentation and clinical risk parameters in patients with B-lineage ALL but not in patients with T-lineage ALL, suggesting that IFN-g plays a distinct role in the immunosurveillance of B-lineage ALL. These results support the hypothesis of an IFN-g-dependent immunosurveillance mechanism in humans and encourage further experimental studies.
